share_log

Catalent Launched New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies

Catalent Launched New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies

Catalent 為細胞和基因療法的端到端供應鏈案例管理推出新服務
Benzinga Real-time News ·  2023/01/24 09:24

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the launch of its new Case Management Service, which has been specifically designed to address the unique challenges associated with the safe and timely delivery of advanced therapies to patients by providing professional supply chain oversight from program start to finish. The supply chain logistics for advanced therapy medicinal products (ATMPs), such as cell and gene therapies, is complex because of their inherent sensitivity, high value, and certain patient-specific complexities of delivering each dose. Ensuring these products are efficiently managed and correctly transported reduces the risk of potential disruption to the manufacturing schedule and, ultimately, the administration of the therapy to the patient.

為全球患者開發和供應更好的治療方法的領先企業Catalent今天宣佈推出其新的病例管理服務，該服務是專門為解決與安全和及時向患者提供先進治療相關的獨特挑戰而設計的，從計劃開始到結束提供專業的供應鏈監督。先進治療藥物產品(ATMP)的供應鏈物流是複雜的，因為它們固有的敏感性、高價值和特定於患者的遞送每個劑量的複雜性。確保這些產品得到有效管理和正確運輸，可降低生產計劃潛在中斷的風險，並最終降低給患者實施治療的風險。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論